CCNU for the treatment of dogs with histiocytic sarcoma |
| |
| Authors: | Skorupski Katherine A Clifford Craig A Paoloni Melissa C Lara-Garcia Ana Barber Lisa Kent Michael S LeBlanc Amy K Sabhlok Aarti Mauldin Elizabeth A Shofer Frances S Couto C Guillermo Sørenmo Karin U |
| |
| Institution: | Departments of Clinical Studies, Matthew J. Ryan Veterinary Hospital, University of Pennsylvania Philadelphia, USA. kskorups@ucdavis.edu |
| |
| Abstract: | BACKGROUND: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown. The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis. HYPOTHESIS: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease. ANIMALS: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU. METHODS: A multi-institutional, retrospective, single-arm cohort study was conducted. Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma. RESULTS: Fifty-nine dogs were treated at 8 institutions. Twenty-three tumor specimens were confirmed to be CD18 positive. Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46% in the 56 dogs with gross measurable disease. All 3 dogs with minimal residual disease experienced tumor relapse but lived 433 days or more after starting CCNU. The median survival of all 59 dogs was 106 days. Thrombocytopenia (< 100,000 platelets/microL) and hypoalbuminemia were found to be negatively associated with prognosis and were predictive of < 1 month survival. CONCLUSIONS AND CLINICAL IMPORTANCE: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors. |
| |
| Keywords: | CD18 Dendritic cell neoplasia Lomustine Malignant histiocytosis |
| 本文献已被 PubMed 等数据库收录！ |
|
